VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
NCT03556228 is a phase 1/2 interventional trial sponsored by VM Oncology, LLC. As of 21 Nov 2026, it is recruiting participants. It studies 4-[[4-Azanyl-3-(4-cyclohexylpiperazin-1-yl)-9,10-bis(oxidanylidene)anthracen-1-yl]amino]benzoic acid and VMD-928 and Pembrolizumab in Adenoid Cystic Carcinoma, Any Solid Tumors Progressed After a Prior Immunotherapy and 23 more conditions. The registry lists an enrollment of 242 participants at 13 sites in 2 countries. The registry lists a start date of 8 Jun 2018 and a primary completion date of 31 Dec 2027. 2 of its registered investigators have a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT03556228 |
| Status | Recruiting |
| Phase | Phase 1/2 |
| Study type | Interventional trial |
| Lead sponsor | VM Oncology, LLC |
| Enrollment | 242 |
| Registered sites | 13 |
| Countries | 2 |
| Conditions | Adenoid Cystic Carcinoma, Any Solid Tumors Progressed After a Prior Immunotherapy, Esophageal Cancer, Head and Neck Cancers, Head and Neck Cancers - Nasopharyngeal, Head and Neck Cancers - Salivary Gland and 19 more conditions |
| Drugs | 4-[[4-Azanyl-3-(4-cyclohexylpiperazin-1-yl)-9,10-bis(oxidanylidene)anthracen-1-yl]amino]benzoic acid and VMD-928 and Pembrolizumab |
| Start | 8 Jun 2018 |
| Primary completion | 31 Dec 2027 |
| Study completion | 30 Jun 2028 |
| Last update posted | 4 Nov 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Clinical Development
VM Oncology
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Providence Medical Foundation (site 209)
Santa Rosa
Ian C Anderson, MDRecruiting
- Hartford Hospital (site 210)
Hartford
Jaykumar Thumar, MDRecruiting
- the George Washington University Cancer Center (site 212)
Washington D.C.
Pavani Chalasani, MD, MPHRecruiting
- Holy Cross Hospital (site 213)
Fort Lauderdale
Georges Azzi, MDRecruiting - Memorial Cancer Institute at Memorial Healthcare Systems (site 132)
Pembroke Pines
Luis E Raez, MDRecruiting
- Englewood Hospital and Medical Center (site 202)
Englewood
Minaxi Jhawer, MDRecruiting - Summit Medical Group (site 205)
Florham Park
Steven Papish, MD, FACPRecruiting - Atlantic Health System, Morristown Medical Center (site 124)
Morristown
Angela Alistar, MDRecruiting
- Presbyterian Kaseman Hospital (site 208)
Albuquerque
Ethan Binder, MDRecruiting
- Weill Cornell Medicine, Cornell University (site 126)
New York
Ashish Saxena, M.D., Ph.D.Recruiting
- Cancer Care Associates of York (site 206)
York
Chanh Huynh, MDRecruiting
- the University of Texas Md Anderson Cancer Center (site 127)
Houston
David S Hong, MDRecruiting
- Panoncology Trials, Hospital Oncologico - Puerto Rico Medical Center, Río Piedras (site 200)
San Juan
Marcia Cruz-Correa, MD, PhDRecruiting
United States, by state
Outside the United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT03556228
Each answer restates registry values shown on this page.
What is NCT03556228?
NCT03556228 is a phase 1/2 interventional trial sponsored by VM Oncology, LLC. It studies 4-[[4-Azanyl-3-(4-cyclohexylpiperazin-1-yl)-9,10-bis(oxidanylidene)anthracen-1-yl]amino]benzoic acid and VMD-928 and Pembrolizumab in Adenoid Cystic Carcinoma, Any Solid Tumors Progressed After a Prior Immunotherapy and 23 more conditions.
Is NCT03556228 recruiting?
As of 21 Nov 2026, it is recruiting participants. 13 of its 13 sites list their own status as recruiting.
Who leads NCT03556228?
The registry names Clinical Development (study chair, VM Oncology) as the overall official.
Where does NCT03556228 run?
The registry lists 13 sites in 2 countries. Most sites are in these countries: United States (12) and Puerto Rico (1).
Which drugs does NCT03556228 study?
The registered drug and biological interventions are 4-[[4-Azanyl-3-(4-cyclohexylpiperazin-1-yl)-9,10-bis(oxidanylidene)anthracen-1-yl]amino]benzoic acid and VMD-928 and Pembrolizumab.
When is NCT03556228 expected to complete?
The registry lists a primary completion date of 31 Dec 2027 and a study completion date of 30 Jun 2028. The sponsor last updated the record on 4 Nov 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.